List of Excipients in Branded Drug FLULAVAL QUADRIVALENT

FLULAVAL QUADRIVALENT Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 24, 2026

FLULAVAL QUADRIVALENT is an egg-based, split-virion, inactivated influenza vaccine manufactured by GlaxoSmithKline Biologicals. Its excipient system is conventional and low-complexity: an isotonic phosphate-salt buffer, residual process chemicals, and, in multidose presentations, thimerosal as a preservative. The largest commercial opportunity is not a new excipient patent around the legacy quadrivalent product. It is the development of differentiated influenza-vaccine presentations using preservative-free multidose technology, improved thermostability, alternative delivery systems, and trivalent formulations aligned with post-2024 U.S. strain recommendations.

What is FLULAVAL QUADRIVALENT and how is it formulated?

FLULAVAL QUADRIVALENT is an intramuscular, split-virion influenza vaccine containing 15 micrograms of hemagglutinin from each of four influenza strains per 0.5 mL dose. The four-strain formulation historically included two influenza A strains and two influenza B lineages.

The vaccine is manufactured using embryonated chicken eggs. The virus is inactivated, disrupted, purified, and formulated as a split-virus antigen preparation. It does not contain an aluminum adjuvant.

Attribute	FLULAVAL QUADRIVALENT profile
Sponsor	GlaxoSmithKline Biologicals
Active product	Inactivated influenza virus split-virion vaccine
Route	Intramuscular
Dose	0.5 mL for most recipients; pediatric dosing can require 0.25 mL
Antigen content	15 mcg hemagglutinin per strain per 0.5 mL
Production platform	Embryonated chicken eggs
Adjuvant	None
Preservative	Thimerosal in applicable multidose-vial presentation; preservative-free presentations also exist
Primary excipient system	Sodium chloride, phosphate salts, potassium and magnesium salts, calcium chloride
Process residuals	May include trace ovalbumin, formaldehyde, sodium deoxycholate, sucrose, and other manufacturing residuals, depending on the presentation and manufacturing lot
FDA status	Licensed seasonal influenza vaccine under a biologics license application

The exact excipient and residual profile should be taken from the applicable U.S. package insert because presentation, manufacturing site, and annual strain update can affect the listed composition.[1]

What excipients are used in FLULAVAL QUADRIVALENT?

The principal formulation excipients are inorganic salts used to control tonicity and pH. The formulation is designed to maintain antigen compatibility during filling, storage, and administration rather than to provide long-term protein stabilization through a complex excipient matrix.

Core formulation excipients

Public labeling identifies a buffer and salt system that can include:

• Sodium chloride
• Monobasic potassium phosphate
• Dibasic sodium phosphate
• Potassium chloride
• Magnesium chloride
• Calcium chloride

These ingredients support isotonicity and pH control. They are widely used in parenteral products and have established regulatory histories.

Manufacturing residuals

Influenza vaccines produced in eggs can contain trace residuals associated with upstream and downstream processing. Depending on the product presentation and lot release specifications, these may include:

• Ovalbumin from the egg-based production substrate
• Formaldehyde used for viral inactivation
• Sodium deoxycholate used during virus disruption
• Sucrose or related stabilizing ingredients
• Residual antibiotics or other process materials, where applicable

These residuals are not interchangeable with intentionally added formulation excipients. From a regulatory and patent perspective, the distinction matters. A claimed formulation may cover an intentionally added stabilizer, while a manufacturing patent may cover removal or control of a residual impurity.

Thimerosal and presentation-specific strategy

The multidose-vial presentation can use thimerosal to control microbial contamination after repeated vial entry. Single-dose syringes and other preservative-free formats avoid that preservative.

This creates a commercial segmentation strategy:

Presentation	Main excipient opportunity	Commercial position
Single-dose syringe	Low-excipient, preservative-free formulation	Retail pharmacy, pediatric, institutional use
Multidose vial	Preservative system and antimicrobial control	Mass immunization and public-sector procurement
Alternative multidose system	Container-closure and aseptic-dose technology	Premium preservative-free institutional product
Pre-filled autoinjector or microneedle format	Device-compatible stabilizer and viscosity control	Convenience and differentiated administration

What formulation patents protect FLULAVAL QUADRIVALENT?

The commercial protection for FLULAVAL QUADRIVALENT has historically depended more on biologics regulation, manufacturing know-how, seasonal supply capability, trademarks, and production infrastructure than on a durable excipient patent estate.

Publicly available labeling does not establish a current, enforceable patent covering the basic sodium chloride-phosphate formulation. The standard excipients are old, widely used materials. A patent claim directed only to the presence of sodium chloride, phosphate salts, or common mineral salts would face substantial novelty and obviousness challenges unless combined with specific concentration ranges, antigen characteristics, stability results, or manufacturing conditions.

Potentially relevant patent categories include:

1. Virus production patents. These may cover egg adaptation, viral propagation, inactivation, splitting, purification, or strain selection.
2. Antigen stabilization patents. Claims may cover sucrose, amino acids, surfactants, polymers, or combinations that improve hemagglutinin stability.
3. Residual-control patents. These may cover methods for reducing ovalbumin, formaldehyde, detergent, or other process impurities.
4. Multidose presentation patents. Claims may address preservative-free repeated-dose access, container closures, vial adapters, and aseptic delivery.
5. Thermostability patents. These may cover formulations that preserve potency during temperature excursions.
6. Delivery-device patents. Microneedle, intradermal, jet-injection, and prefilled-device claims can create separate commercial barriers.
7. Trivalent or quadrivalent antigen-combination patents. These are more likely to involve strain combinations, dose ratios, or manufacturing methods than simple excipient composition.

How strong is the excipient patent estate?

The core excipient estate is likely weak as a standalone composition-of-matter position because the formulation uses conventional parenteral salts and buffer components. The stronger barriers are:

• Scale-up of egg-based manufacturing
• Strain-specific process validation
• Biological potency assays
• Sterility and lot-release controls
• Supply of qualified eggs and manufacturing capacity
• Regulatory history with FDA
• Institutional purchasing relationships
• Know-how around antigen yield and consistency

A competitor could generally avoid a narrow excipient claim by changing buffer concentrations, substituting a different stabilizer, selecting a different presentation, or using a cell-based or recombinant manufacturing platform.

When does FLULAVAL QUADRIVALENT lose exclusivity?

FLULAVAL QUADRIVALENT does not have an exclusivity profile identical to a conventional small-molecule drug.

The product is licensed as a biologic, and the relevant regulatory framework is the Public Health Service Act rather than an ANDA-based generic pathway. A reference biologic licensed after the effective date of the Biologics Price Competition and Innovation Act can receive 12 years of reference-product exclusivity, subject to FDA’s product-specific determination.[2]

The original quadrivalent U.S. approval occurred in the early 2010s. Any initial statutory biologic exclusivity tied to that approval would not create a current long-term barrier to competing influenza vaccines. Annual strain changes, supplemental approvals, or manufacturing updates generally do not restart a new 12-year reference-product exclusivity period.

Seasonal influenza vaccines also compete in a market where several manufacturers receive separate annual approvals or strain updates. The relevant commercial question is therefore not simply whether FLULAVAL QUADRIVALENT exclusivity has expired. It is whether a competitor can obtain seasonal licensure, demonstrate manufacturing consistency, secure supply, and win public and private contracts.

What is the Orange Book status of FLULAVAL QUADRIVALENT?

FLULAVAL QUADRIVALENT is not typically analyzed through the conventional Orange Book patent-listing framework used for small-molecule drugs.

Biologics licensed under the Public Health Service Act are generally evaluated through the Purple Book and the biologics approval framework. The Orange Book does not provide the primary patent-certification mechanism for a competing influenza vaccine.

As a result:

• A conventional Paragraph IV ANDA challenge is not the normal pathway.
• There is no ordinary Orange Book patent-certification timetable comparable to a branded tablet.
• Competitive entry depends on biologics licensure, seasonal manufacturing capability, and product-specific FDA review.
• Patent disputes can still occur, but they are more likely to involve manufacturing, delivery systems, formulations, or platform technology.

Are Paragraph IV challenges or biosimilar risks relevant?

Paragraph IV litigation

A Paragraph IV challenge is generally not the expected entry mechanism for FLULAVAL QUADRIVALENT. A rival influenza vaccine manufacturer would normally pursue its own biologics license or another applicable FDA pathway rather than file an ANDA certifying invalidity or noninfringement of Orange Book patents.

Biosimilar risk

Traditional biosimilar risk is limited because seasonal influenza vaccines are not typical biosimilar products. The antigen composition changes by season, and competing vaccines are usually developed as independently manufactured products.

The more realistic competitive threats are:

• Another egg-based inactivated vaccine
• A cell-based influenza vaccine
• A recombinant hemagglutinin vaccine
• A high-dose or adjuvanted vaccine for older adults
• A next-generation universal influenza vaccine
• A vaccine using a novel delivery device

The competitive threat is therefore product substitution rather than biosimilar erosion.

How does FLULAVAL QUADRIVALENT compare with competing influenza vaccines?

Product category	Excipient profile	Main differentiation	Risk to FLULAVAL
Standard-dose egg-based vaccine	Conventional salts and buffer; may be preservative-free or thimerosal-preserved	Price, supply, established use	High
Cell-based vaccine	Similar parenteral excipient architecture, with different process residual profile	Avoids egg production and may improve strain matching	Moderate to high
Recombinant vaccine	Protein-focused formulation and manufacturing system	Faster production and no egg adaptation	Moderate
Adjuvanted vaccine	Includes an immune-stimulating adjuvant system	Enhanced immune response in older adults	Segment-specific
High-dose vaccine	Higher antigen content, with formulation and device implications	Older-adult immunogenicity	High in the senior segment
Intranasal vaccine	Mucosal delivery and distinct excipient requirements	Needle-free administration	Moderate
Microneedle or intradermal vaccine	Device-dependent formulation	Reduced needle burden and potential dose sparing	Long-term

The basic FLULAVAL excipient system is cost-efficient but does not create a strong clinical differentiation. Commercial value would come from a measurable benefit such as longer stability, lower cold-chain cost, improved tolerability, easier administration, or lower antigen dose.

What commercial opportunities exist for FLULAVAL excipients?

1. Preservative-free multidose technology

A preservative-free multidose vial or cartridge could address institutional demand for reduced exposure to thimerosal while preserving the logistical advantages of multidose packaging.

The technology would need to control:

• Microbial ingress after repeated access
• Container-closure integrity
• Dose uniformity
• In-use stability
• Compatibility with rubber stoppers and vial coatings
• Administration-site workflow

This opportunity is more likely to generate device and container-closure patents than a conventional excipient patent.

2. Thermostable formulations

A stabilizer system that protects hemagglutinin during short-term temperature excursions could reduce wastage and improve distribution in markets with constrained cold-chain infrastructure.

Candidate approaches include:

• Sucrose or trehalose systems
• Amino-acid stabilizers
• Nonionic surfactants
• Polymer or hydrogel matrices
• Controlled-drying or lyophilized presentations

The key patent requirement would be demonstrated potency retention under defined stress conditions. A generic claim to “a stabilizer” would likely be weak. Stronger claims would specify concentrations, antigen composition, storage conditions, and potency outcomes.

3. Lyophilized or dried influenza vaccine

A dried vaccine could materially reduce cold-chain dependence. The commercial barriers include reconstitution time, dose accuracy, antigen recovery, container technology, and manufacturing cost.

A lyophilized FLULAVAL-type product would require compatibility testing for:

• Hemagglutinin recovery
• Split-virus particle integrity
• Residual moisture
• Cake structure
• Reconstitution volume
• Stopper and seal performance

This is a higher-value formulation opportunity but also a higher-risk development program.

4. Pediatric formulation and dose-volume optimization

Pediatric administration creates an opportunity for a lower-volume, ready-to-use product. A formulation or device that enables consistent 0.25 mL delivery could reduce waste and simplify vaccination workflow.

Commercial claims could focus on:

• Low dead-volume syringes
• Integrated dose markings
• Reduced injection volume
• Improved pediatric administration
• Improved stability in prefilled systems

5. Intradermal and microneedle delivery

Intradermal delivery could support antigen dose sparing or improve acceptance among needle-averse patients. The excipient challenge is maintaining antigen stability at the lower fill volumes and higher surface-area exposure associated with microneedle devices.

Potentially protectable elements include:

• Coated microneedle matrices
• Dissolvable polymer systems
• Dry-state antigen stabilization
• Device-specific antigen loading
• Release profiles
• Skin-penetration control

6. Combination respiratory vaccines

A future commercial platform could combine influenza antigens with other respiratory-virus antigens. The excipient burden would increase because each antigen may have different pH, surfactant, and stability requirements.

The main development issues would be:

• Antigen-antigen compatibility
• Potency assay interference
• Adsorption to container surfaces
• Differential degradation
• Increased dose volume
• New clinical immunogenicity requirements

What FDA regulatory issues affect excipient commercialization?

FDA will assess both the excipient and its function in the finished vaccine. A new excipient, novel concentration, or new route of administration can trigger additional chemistry, manufacturing, and controls requirements.

Important regulatory considerations include:

• Excipient identity and grade
• Compendial status and supplier qualification
• Endotoxin and bioburden controls
• Sterility assurance
• Extractables and leachables
• Antigen adsorption
• Hemagglutinin potency
• Split-virus particle integrity
• Container-closure compatibility
• Stability under ICH and vaccine-specific conditions
• Pediatric exposure and route-specific safety
• Residual process impurity limits

The use of an excipient with prior parenteral precedent can reduce regulatory friction, but it does not eliminate the need to demonstrate compatibility with the influenza antigen and manufacturing process.[3]

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barrier is not access to common excipients. It is reproducible antigen production at seasonal scale.

A competitive excipient program must account for:

1. Egg-derived variability. Egg supply and viral yield can vary by strain and season.
2. Antigen degradation. Hemagglutinin can lose conformational integrity during processing or storage.
3. Detergent and residual removal. Split-virus processing must control sodium deoxycholate and other residuals.
4. Potency testing. Formulation changes can affect assay performance even when the product remains clinically comparable.
5. Cold-chain economics. A more expensive stabilizer may be justified only if it reduces wastage or distribution cost.
6. Supplier concentration. Sterile-grade excipients and specialty packaging components may require dual sourcing.
7. Regulatory comparability. A new excipient system can require bridging studies to the licensed product.

The strongest intellectual-property strategy would combine formulation claims with manufacturing-process, container-closure, and device claims. A single broad excipient claim would provide limited protection.

Which licensing deals and partnering models are commercially relevant?

A direct licensing deal around FLULAVAL QUADRIVALENT’s basic excipients is unlikely to be the most attractive structure because the core formulation uses established materials. More practical partnering models include:

• GSK licensing a proprietary thermostabilizer
• A packaging company partnering on preservative-free multidose delivery
• A device company supplying microneedle or intradermal administration technology
• A contract manufacturer developing dried or concentrated vaccine presentations
• A specialty-excipient supplier providing a novel stabilizer under a supply and royalty agreement
• A regional vaccine manufacturer obtaining rights to a low-cold-chain presentation

The preferred deal structure would protect formulation know-how, manufacturing parameters, and device integration rather than rely solely on a composition patent.

What generic launch risks exist for FLULAVAL QUADRIVALENT?

A classic generic launch scenario is unlikely. The relevant entry scenarios are:

Entry scenario	Timing risk	Commercial impact
Competing standard-dose egg-based vaccine	Near-term and recurring	High price and contract pressure
Cell-based or recombinant replacement	Seasonal and platform-driven	High in procurement-sensitive markets
Preservative-free multidose product	Medium term	High for hospitals and public programs
Thermostable vaccine	Medium to long term	High in emerging markets
Microneedle or intradermal vaccine	Long term	Segment-specific but potentially disruptive
Universal influenza vaccine	Long term	Structural replacement risk

The most immediate risk is annual competition from other licensed influenza vaccines. The product’s historical quadrivalent designation also faces market transition risk because U.S. influenza vaccines moved toward trivalent compositions after FDA recommendations following the disappearance of the B/Yamagata lineage from routine circulation.[4]

How should an excipient investment be prioritized?

A practical ranking is:

Opportunity	Technical feasibility	Patent potential	Commercial attractiveness
Preservative-free multidose presentation	Medium	Medium to high	High
Thermostable liquid formulation	Medium	High	High
Lyophilized vaccine	Low to medium	High	Medium to high
Pediatric low-volume delivery	High	Medium	Medium
Microneedle delivery	Medium	High	Medium to high
Basic buffer substitution	High	Low	Low
Novel adjuvant for standard FLULAVAL	Medium	High	Segment-specific
Combination respiratory vaccine	Low to medium	High	High but long-term

The strongest near-term opportunity is a preservative-free, multidose, container-closure system supported by improved in-use stability. The strongest long-term opportunity is a thermostable or dried influenza vaccine compatible with existing antigen manufacturing.

Key Takeaways

• FLULAVAL QUADRIVALENT uses a conventional salt and phosphate-buffer excipient system.
• The product has no obvious high-value patent position based solely on its basic excipients.
• Residual ovalbumin, formaldehyde, sodium deoxycholate, and related process materials should be analyzed separately from intentional formulation excipients.
• Traditional Paragraph IV litigation and generic substitution are not the principal competitive risks.
• Competing influenza vaccines, cell-based production, recombinant antigens, high-dose products, and adjuvanted vaccines create greater commercial pressure.
• The most promising excipient opportunities are thermostability, preservative-free multidose access, pediatric dosing, and dried or microneedle presentations.
• U.S. movement from quadrivalent toward trivalent influenza vaccines reduces the standalone future value of a quadrivalent-specific excipient program.
• Strong protection would combine formulation, manufacturing, packaging, and delivery-device claims.

FAQs

Can FLULAVAL QUADRIVALENT be reformulated with trehalose?

Potentially, but the change would require compatibility, potency, stability, sterility, and regulatory comparability studies. Trehalose could support a thermostability strategy, but its value would depend on demonstrated potency retention and a commercially meaningful reduction in cold-chain loss.

Does FLULAVAL QUADRIVALENT contain an aluminum adjuvant?

No. FLULAVAL QUADRIVALENT is a non-adjuvanted, split-virion influenza vaccine. This distinguishes it from adjuvanted influenza products designed primarily for older adults.

Is thimerosal present in every FLULAVAL QUADRIVALENT dose?

No. Thimerosal is associated with applicable multidose-vial presentations. Preservative-free presentations, including single-dose formats, are available or have been marketed depending on the applicable product configuration and season.

Can a competitor launch a generic version of FLULAVAL QUADRIVALENT?

A conventional ANDA generic launch is not the normal pathway. A competitor would generally develop and license its own influenza vaccine through the applicable biologics and seasonal vaccine framework.

Does changing the excipient create a new biologic exclusivity period?

Generally, no. A formulation change or annual strain update does not automatically create a new 12-year reference-product exclusivity period. The regulatory effect depends on the nature of the supplement, the approval pathway, and FDA’s product-specific determinations.

References

1. U.S. Food and Drug Administration. (2023). FLULAVAL QUADRIVALENT prescribing information. GlaxoSmithKline Biologicals.

2. U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biologic products. https://www.fda.gov

3. U.S. Food and Drug Administration. (2019). Questions and answers on quality considerations for central nervous system drug products and biological products. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Vaccines for the 2024-2025 influenza season. https://www.fda.gov